deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07323732

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Interstitial Lung Disease Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) NSCLC NSCLC Stage II NSCLC, Stage I Non Small Cell Lung Cancer Non-small Cell Lung Cancer Stage I Non-small Cell Lung Cancer Stage II
Interventions BIO 300
Updated 2 times since 2026 Last updated: Mar 2, 2026 Started: Jan 6, 2026 Primary completion: Jan 6, 2029 Completion: Jan 6, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Interstitial Lung Disease and Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) and is currently actively recruiting participants. Memorial Sloan Kettering Cancer Center leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshotRecruiting~Mar 2026 – present · 4 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2026

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations